Protect Yourself From a Lapse in Coverage
For every month in which you use an eligible CSL Behring immunology therapy, you will earn 1 Assurance point.
If you have been enrolled for at least 3 months, or earned at least 3 points, by the time of your insurance lapse, you will be eligible to redeem your points as follows:
Multiple points (in increments of 3) may be redeemed within 1 month for a 30-day prescription refill. The number of points that may be redeemed for 1 prescription
cannot exceed 12.
Please review the program Terms and Conditions for a complete description of CSL Behring Assurance.
Important Safety Information for Hizentra
WARNING: Thrombosis (blood clotting) can occur with immune globulin products, including Hizentra. Risk factors can include: advanced age, prolonged immobilization, a history of blood clotting or hyperviscosity (blood thickness), use of estrogens, installed vascular catheters, and cardiovascular risk factors.
If you are at high risk of thrombosis, your doctor will prescribe Hizentra at the minimum dose and infusion rate practicable and will monitor you for signs of thrombosis and hyperviscosity. Always drink sufficient fluids before administration.
Immune Globulin Subcutaneous (Human), Hizentra®, treats various forms of primary immunodeficiency (PI) in patients age 2 and over.
Tell your doctor if you have had a serious reaction to other immune globulin medicines or have been told you also have a deficiency of the immunoglobulin called IgA, as you might not be able to take Hizentra. You should not take Hizentra if you know you have hyperprolinemia (too much proline in your blood).
Infuse Hizentra under your skin only; do not inject into a blood vessel.
Allergic reactions can occur with Hizentra. If your doctor suspects you are having a bad allergic reaction or are going into shock, treatment will be discontinued. Immediately tell your doctor or go to the emergency room if you have signs of such a reaction, including hives, trouble breathing, wheezing, dizziness, or fainting.
Tell your doctor about any side effects that concern you. Immediately report symptoms that could indicate a blood clot, including pain and/or swelling of an arm or leg, with warmth over affected area; discoloration in arm or leg; unexplained shortness of breath; chest pain or discomfort that worsens with deep breathing; unexplained rapid pulse; and numbness or weakness on one side of the body. Your doctor will also monitor symptoms that could indicate hemolysis (destruction of red blood cells), and other potentially serious reactions that have been seen with Ig treatment, including aseptic meningitis syndrome (brain swelling); kidney problems; and transfusion-related acute lung injury.
The most common drug-related adverse reactions in the clinical trial for Hizentra were swelling, pain, redness, heat or itching at the site of injection; headache; back pain; diarrhea; tiredness; cough; rash; itching; nausea and vomiting.
Hizentra is made from components of human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
Before being treated with Hizentra, inform your doctor if you are pregnant, nursing or plan to become pregnant. Vaccines (such as measles, mumps and rubella) might not work well if you are using Hizentra. Before receiving any vaccine, tell the healthcare professional you are being treated with Hizentra.
Please see full prescribing information for Hizentra, including boxed warning and the patient product information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Important Safety Information for Privigen
Immune Globulin Intravenous (Human), 10% Liquid, Privigen®, is approved for the treatment of primary immunodeficiency (PI), and to raise platelet counts in patients with chronic immune thrombocytopenic purpura (ITP).
- Thrombosis (blood clotting) can occur with immune globulin products, including Privigen. Risk factors may include advanced age, prolonged immobilization, a history of blood clotting or hyperviscosity (thick blood), use of estrogens, installed vascular catheters, and cardiovascular risk factors.
- In predisposed patients, kidney malfunction and acute kidney failure, potentially fatal, can occur with the administration of human immune globulin intravenous (IGIV) products. Kidney problems occur more commonly in patients receiving IGIV products that contain sucrose. Privigen does not contain sucrose.
- If you are at high risk of thrombosis or kidney problems, your doctor will prescribe and administer Privigen at the minimum dose and infusion rate practicable, and will monitor you for signs and symptoms of thrombosis and viscosity, as well as kidney function. Always drink sufficient fluids before administration.
See your doctor for a full explanation and the full prescribing information for complete boxed warning.
Treatment with Privigen might not be possible if your doctor determines you have hyperprolinemia (too much proline in the blood) or are IgA-deficient with antibodies to IgA and a history of hypersensitivity. Tell your doctor if you have previously had anaphylaxis (shock) or any other severe reaction to the administration of human immune globulin. Inform your physician if you notice early signs of hypersensitivity reactions to administration of Privigen, including hives, tightness of the chest, wheezing, or shock.
If you notice a decrease in urine output, sudden weight gain, fluid retention, and/or shortness of breath following infusion with Privigen, contact your doctor immediately. Immediately report symptoms that could indicate a blood clot, including pain and/or swelling or discoloration of an arm or leg, shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid pulse, and numbness or weakness on one side of the body. Inform your doctor if you experience severe headache; a stiff neck; excessive drowsiness or fatigue; fever; sensitivity to light or painful eye movements; nausea; increased heart rate; yellowing of the skin or eyes, and/or dark-colored urine.
Privigen is made from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.
Administration of immunoglobulins can impair the effectiveness of live virus vaccines (eg, measles, mumps, and rubella) or lead to misinterpretation of test results. Before receiving any vaccine, tell the immunizing physician if you have had recent therapy with Privigen.
In clinical trials of Privigen, the most common adverse reactions seen in patients with PI, included headache, fatigue, nausea, and chills. In studies of patients being treated for chronic ITP, the most common adverse reactions included headache, anemia, and nausea. These are not the only adverse reactions possible with Privigen. Speak with your physician about any side effect that bothers you or does not go away.
For more information about Privigen, please see full prescribing information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Important Safety Information for Carimune NF
Carimune® NF, Nanofiltered Immune Globulin Intravenous (Human) is indicated for the maintenance treatment of patients with primary immunodeficiencies (PI), such as common variable immunodeficiency, X-linked agammaglobulinemia, and severe combined immunodeficiency, as well as for for acute and chronic immune thrombocytopenic purpura (ITP).
WARNING: THROMBOSIS, RENAL DYSFUNCTION or ACUTE RENAL FAILURE
Thrombosis may occur with immune globulin products, including Carimune NF. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis might occur in absence of known risk factors.
Renal dysfunction, acute renal failure, osmotic nephrosis, and death can occur in predisposed patients with immune globulin intravenous (IGIV) products, including Carimune NF. Patients predisposed to renal dysfunction include those with any degree of preexisting renal insufficiency, diabetes mellitus, age over 65, volume depletion, sepsis, paraproteinemia, and those receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. Carimune NF contains sucrose.
For patients at risk of thrombosis, renal dysfunction or acute renal failure, administer Carimune NF at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
See full prescribing information for full boxed warning.
Carimune NF is contraindicated in patients who have had anaphylactic or severe systemic reactions to the administration of human immune globulin. Individuals with selective IgA deficiency who possess antibody to IgA should only receive Carimune NF with utmost caution due to risk of severe, immediate hypersensitivity reactions, including anaphylaxis.
Increases in creatinine and blood urea nitrogen with progression to oliguria or anuria requiring dialysis have been observed as soon as one to two days following IGIV infusion. Severe renal adverse events have included acute renal failure, acute tubular nephrosis, proximal tubular nephropathy, and osmotic nephrosis.
Patients receiving Carimune NF should be monitored for clinical signs and symptoms of hemolysis, as well pulmonary adverse reactions, including TRALI. An aseptic meningitis syndrome (AMS) has been reported to occur infrequently with IVIG—more frequently in association with high dose (2 g/kg) treatment.
Inflammatory adverse reactions have been observed; they may become apparent within 30 minutes to an hour after beginning infusion. Slow or temporarily stop infusion if patient experiences facial flushing, tightness in chest, chills, fever, nausea, dizziness or other unusual response; stop infusion immediately if anaphylaxis or severe reaction occurs. Headache, usually mild, is the most common adverse reaction; mild hemolysis, arthralgia, myalgia, and transient skin reactions have also been reported.
Carimune NF is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
Carimune NF should be given to a pregnant woman only if clearly needed.
Please see full prescribing information, including boxed warning on thrombosis and renal dysfunction/failure.